声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。在快速变化的政策与市场环境下,医药企业战略和组织架构正不断调整,由此也导致了频繁的人员变动。2025开年至今,国内外各大药企战略调整、人事更迭一直十分频繁,强生、恒瑞、荣昌生物等都已宣布新的人事任命。强生自2025年3月1日起,强生创新制药中国区副总裁、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.